Renal Cell Carcinoma News
Patients in all subgroups who received adjuvant sunitinib had a DFS benefit compared with placebo, including patients who were at a higher risk of recurrence.
Researchers hypothesized that by reversing the order and administering targeted therapy prior to CN, tumor size would be reduced prior to surgery and lead to improved outcomes.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
In the open-label, phase 2 CABOSUN trial, 157 patients with untreated, locally advanced or metastatic clear cell RCC were randomly assigned to receive cabozantinib or sunitinib.
The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).
Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.
Researchers evaluated telomere length samples from 184 patients with von Hippel-Lindau syndrome to determine whether shortened telomere length can predict cancer risk.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.
Savolitinib was tolerable, safe, and may have treatment potential for patients with MET-driven papillary renal cell carcinoma.
Downregulation of apoptosis stimulating of p53 protein 1 confers drug resistance and permits tumor growth in clear cell renal cell carcinoma.
Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.
A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.
Overall, 3.5 million cells were analyzed and 17 major tumor-associated macrophage phenotypes were identified.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
Study results suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors.
Two children with recurrent metastatic, TFE3 fusion-positive RCC that expressed MET experienced "prolonged disease control" following treatment with cabozantinib.
Study findings suggest that BET inhibitors might be a promising avenue of drug-development against RCC.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC
- Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC